Half-Year 2022 Financial and Clinical Trials Update
HY 2022: Good Group performance
Group sales +5% driven by both divisions
·
Pharma portfolio performing well (+3%) outgrowing biosimilar erosion
Diagnostics with strong growth momentum (+11%) including good base business growth (+6%)
Key products growing strongly; new launches with significant sales potential
•
•
•
Pharma growth drivers Hemlibra, Ocrevus, Evrysdi, Phesgo and Tecentriq with strong momentum
Promising new launches with Vabysmo in ophthalmology and Polivy & Lunsumio in hematology
Diagnostics receives EUA for SARS-CoV-2 DUO test and BDD for Alzheimer's disease amyloid plasma panel tests*;
new launches of Elecsys® HCV DUO Immunoassay and Monkeypox assays; Benchmark Ultra PLUS and Digital
Pathology slide scanner
Upcoming late-stage newsflow in 2022
•
Pharma: Tecentriq in adjuvant HCC and neoadjuvant NSCLC; tiragolumab + Tecentriq in esophageal cancer;
Venclexta in MM; Vabysmo in RVO; Susvimo in DME & DR and gantenerumab in Alzheimer's disease
•
Diagnostics: ElecsysⓇ IGRA SARS-CoV-2, ElecsysⓇ pTau/AB42 ratio Gen2 CSF (FDA), Digital LightCycler, cobas® 5800
(FDA), cobas pure (FDA), cobas pulse (FDA)
Growth rates at CER (Constant exchange Rates); * Data will be published at AAIC in August 22
Roche
6View entire presentation